IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+19.03%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$444M
AUM Growth
+$444M
(-10%)
Cap. Flow
-$53.8M
Cap. Flow
% of AUM
-12.13%
Top 10 Holdings %
Top 10 Hldgs %
35.87%
Holding
93
New
28
Increased
20
Reduced
11
Closed
33
Top Buys
| 1 |
Moderna
MRNA
|
$18M |
| 2 |
Quest Diagnostics
DGX
|
$15.6M |
| 3 |
Cigna
CI
|
$14.9M |
| 4 |
Universal Health Services
UHS
|
$14.1M |
| 5 |
Intuitive Surgical
ISRG
|
$11.7M |
Top Sells
| 1 |
Baxter International
BAX
|
$16.2M |
| 2 |
CRISPR Therapeutics
CRSP
|
$14.4M |
| 3 |
Boston Scientific
BSX
|
$13.6M |
| 4 |
Biogen
BIIB
|
$13.4M |
| 5 |
CVS Health
CVS
|
$12.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Danaher
DHR
$143B
| – | – |
-30,000
| Closed | -$7.75M |
|
|
77
CVS Health
CVS
$93B
| – | – |
-130,000
| Closed | -$12.4M |
|
|
78
CRISPR Therapeutics
CRSP
$4.82B
| – | – |
-220,000
| Closed | -$14.4M |
|
|
79
Boston Scientific
BSX
$159B
| – | – |
-350,000
| Closed | -$13.6M |
|
|
BPMC
80
DELISTED
Blueprint Medicines
BPMC
| – | – |
-93,000
| Closed | -$6.13M |
|
|
81
Biogen
BIIB
$20.8B
| – | – |
-50,000
| Closed | -$13.4M |
|
|
82
Baxter International
BAX
$12.1B
| – | – |
-300,000
| Closed | -$16.2M |
|
83
Arcturus Therapeutics
ARCT
$467M
| – | – |
-130,000
| Closed | -$1.93M |
|
84
Apellis Pharmaceuticals
APLS
$3.51B
| – | – |
-70,000
| Closed | -$4.78M |
|
|
AMED
85
DELISTED
Amedisys
AMED
| – | – |
-33,000
| Closed | -$3.19M |
|
86
Alkermes
ALKS
$4.95B
| – | – |
-200,000
| Closed | -$4.47M |
|
87
Agios Pharmaceuticals
AGIO
$2.36B
| – | – |
-100,000
| Closed | -$2.83M |
|
88
Illumina
ILMN
$15.2B
| – | – |
-30,000
| Closed | -$5.72M |
|
89
Kura Oncology
KURA
$732M
| – | – |
-500,000
| Closed | -$6.83M |
|
90
Lifestance Health
LFST
$2.14B
| – | – |
-525,000
| Closed | -$3.48M |
|
91
Eli Lilly
LLY
$661B
| – | – |
-25,000
| Closed | -$8.08M |
|
92
McKesson
MCK
$85.9B
| – | – |
-30,000
| Closed | -$10.2M |
|
93
Madrigal Pharmaceuticals
MDGL
$9.7B
| – | – |
0
| – | – |
|